查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1556577

非侵入性糖尿病治療市場報告：2030 年趨勢、預測與競爭分析

Non-Invasive Diabetes Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

非侵入性糖尿病治療的趨勢與預測

預計2024年至2030年全球非侵入性糖尿病治療市場將以5.6%的複合年成長率成長。該市場的主要促進因素是糖尿病盛行率的上升以及糖尿病患者對自我藥療的日益偏好。全球非侵入性糖尿病治療市場未來性，在醫院、居家醫療和診所市場都有機會。

無創糖尿病治療按細分領域

該研究包括按類型、應用和地區分類的全球非侵入性糖尿病治療預測。

非侵入性糖尿病治療市場洞察

Lucintel 預測，吸入型胰島素預計將在預測期內達到最高成長。

在市場上，居家醫療預計將在預測期內實現最高成長。

由於人口中糖尿病的高盛行率以及該地區主要企業的存在，預計北美在預測期內將出現最高的成長。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球非侵入性糖尿病治療市場預計將以5.6%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 此市場的主要促進因素是糖尿病盛行率的上升以及糖尿病患者對自我藥療的日益偏好。

Q3.市場的主要細分市場是：

A3. 非侵入性糖尿病治療市場未來性廣闊，在醫院、居家醫療和診所市場都有機會。

Q4.市場的主要企業是：

A4. 非侵入性糖尿病治療的主要企業有：

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計吸入胰島素在預測期內將經歷最高成長。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 北美地區預計將在預測期內實現最高成長，因為該地區擁有大量糖尿病人口和主要企業。

Q7. 可以客製化報告嗎？

A7. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球非侵入性糖尿病治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球非侵入性糖尿病治療市場趨勢（2018-2023）與預測（2024-2030）
  • 全球非侵入性糖尿病治療市場（按類型）
    • 口服胰島素
    • 頰含胰島素
    • 眼藥水 胰島素
    • 吸入胰島素
    • 鼻用胰島素
    • 經皮的
    • 其他
  • 全球非侵入性糖尿病治療市場（按應用）
    • 醫院
    • 居家醫療
    • 診所
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球非侵入性糖尿病治療市場區域分佈
  • 北美無創糖尿病治療市場
  • 歐洲無創糖尿病治療市場
  • 亞太非侵入性糖尿病治療市場
  • 其他區域非侵入性糖尿病治療市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球非侵入性糖尿病治療市場按類型分類的成長機會
    • 全球非侵入性糖尿病治療市場的應用成長機會
    • 全球非侵入性糖尿病治療市場按地區成長機會
  • 全球非侵入性糖尿病治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球非侵入性糖尿病治療市場的產能
    • 全球非侵入性糖尿病治療市場的合併、收購與合資
    • 認證和許可

第7章主要企業概況

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories
簡介目錄

Non-Invasive Diabetes Therapy Trends and Forecast

The future of the global non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets. The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030. The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Non-Invasive Diabetes Therapy by Segment

The study includes a forecast for the global non-invasive diabetes therapy by type, application, and region.

Non-Invasive Diabetes Therapy Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Oral Insulin
  • Buccal Insulin
  • Ocular Insulin
  • Inhaled Insulin
  • Nasal Insulin
  • Transdermal
  • Others

Non-Invasive Diabetes Therapy Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Home Care Settings
  • Clinics
  • Others

Non-Invasive Diabetes Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Non-Invasive Diabetes Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies non-invasive diabetes therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the non-invasive diabetes therapy companies profiled in this report include-

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories

Non-Invasive Diabetes Therapy Market Insights

Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Within this market, home care setting is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Features of the Global Non-Invasive Diabetes Therapy Market

Market Size Estimates: Non-invasive diabetes therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Non-invasive diabetes therapy market size by type, application, and region in terms of value ($B).

Regional Analysis: Non-invasive diabetes therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the non-invasive diabetes therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the non-invasive diabetes therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for non-invasive diabetes therapy market?

Answer: The global non-invasive diabetes therapy market is expected to grow with a CAGR of 5.6% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the non-invasive diabetes therapy market?

Answer: The major drivers for this market are rising prevalence of diabetes and growing focus on self-care among diabetes patients.

Q3. What are the major segments for non-invasive diabetes therapy market?

Answer: The future of the non-invasive diabetes therapy market looks promising with opportunities in the hospital, home care setting, and clinic markets.

Q4. Who are the key non-invasive diabetes therapy market companies?

Answer: Some of the key non-invasive diabetes therapy companies are as follows:

  • Bio Tex
  • Calisto Medical
  • Dexcom
  • Bayer
  • ACON Laboratories

Q5. Which non-invasive diabetes therapy market segment will be the largest in future?

Answer: Lucintel forecasts that inhaled insulin is expected to witness the highest growth over the forecast period.

Q6. In non-invasive diabetes therapy market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period due to high diabetes prevalence among population and presence of key players in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the non-invasive diabetes therapy market by type (oral insulin, buccal insulin, ocular insulin, inhaled insulin, nasal insulin, transdermal, and others), application (hospitals, home care settings, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Non-Invasive Diabetes Therapy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Non-Invasive Diabetes Therapy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Non-Invasive Diabetes Therapy Market by Type
    • 3.3.1: Oral Insulin
    • 3.3.2: Buccal Insulin
    • 3.3.3: Ocular Insulin
    • 3.3.4: Inhaled Insulin
    • 3.3.5: Nasal Insulin
    • 3.3.6: Transdermal
    • 3.3.7: Others
  • 3.4: Global Non-Invasive Diabetes Therapy Market by Application
    • 3.4.1: Hospitals
    • 3.4.2: Home Care Settings
    • 3.4.3: Clinics
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Non-Invasive Diabetes Therapy Market by Region
  • 4.2: North American Non-Invasive Diabetes Therapy Market
    • 4.2.1: North American Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.2.2: North American Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
  • 4.3: European Non-Invasive Diabetes Therapy Market
    • 4.3.1: European Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.3.2: European Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
  • 4.4: APAC Non-Invasive Diabetes Therapy Market
    • 4.4.1: APAC Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.4.2: APAC Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others
  • 4.5: ROW Non-Invasive Diabetes Therapy Market
    • 4.5.1: ROW Non-Invasive Diabetes Therapy Market by Type: Oral Insulin, Buccal Insulin, Ocular Insulin, Inhaled Insulin, Nasal Insulin, Transdermal, and Others
    • 4.5.2: ROW Non-Invasive Diabetes Therapy Market by Application: Hospitals, Home Care Settings, Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Type
    • 6.1.2: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Application
    • 6.1.3: Growth Opportunities for the Global Non-Invasive Diabetes Therapy Market by Region
  • 6.2: Emerging Trends in the Global Non-Invasive Diabetes Therapy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Non-Invasive Diabetes Therapy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Non-Invasive Diabetes Therapy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bio Tex
  • 7.2: Calisto Medical
  • 7.3: Dexcom
  • 7.4: Bayer
  • 7.5: ACON Laboratories